NEW YORK, Nov. 2 /PRNewswire/ -- According to the World Health Organization, more than 216,000 people worldwide are diagnosed each year with pancreatic cancer and the prognosis for patients with pancreatic cancer is generally grim. That is why the news that the FDA has approved Tarceva(R) in combination with chemotherapy is so significant. Phase III study results found that patients receiving Tarceva(R) demonstrated a 23 percent improvement in overall survival. Tarceva(R) is a once-daily oral tablet already approved for use in non-small cell lung cancer (NSCLC) for patients whose disease has progressed after one or more courses of chemotherapy.
ADDITIONAL RESOURCES: Video, hard copy requests, downloadable MPEG2, contact information and more available at http://www.prnewswire.com/broadcast/22911/consumer.shtml
VIDEO PROVIDED BY: Genentech, Inc. and OSI, Inc.
Video: http://www.prnewswire.com/broadcast/22911/consumer.shtmlGenentech, Inc.; OSI, Inc.CONTACT: MultiVu Media Relations, 800-653-5313 EXT. 3
Web site: http://www.multivu.com//
